Journal
The GLP-1 Price-Change Ledger: Every Dated Move in Our Database, 2026
Released: Last reviewed:
The short answer
Prices in this market move — promotions open and close, floors get undercut, refill conditions quietly govern what a listed number really costs — and a comparison page that only shows today's figure erases the movement a buyer actually needs to see. This ledger records every dated price change in our database, each entry carrying its capture dates and its evidentiary status. The rule that governs the whole page: a promotional rate is always labeled as one, the standard rate card stays on record beside it, and no promotional figure is ever silently substituted for a standard one. The current entries: on October 15, 2026, Eden listed tirzepatide at one hundred twenty-nine dollars and semaglutide at ninety-nine dollars a month, and NexLife's one hundred sixty-nine dollar tirzepatide and one hundred thirty-nine dollar semaglutide monthly prices were recorded as standing prices; in the August database update the semaglutide month-to-month floor passed from Oak Longevity at one hundred thirty-three dollars to bmiMD at one hundred twenty-nine, and the twelve-month semaglutide floor dropped to a ninety-nine-dollar tier; NovoCare's introductory Wegovy pricing runs through December 31; and LillyDirect's vial prices remain conditional on a forty-five-day refill window.
How an entry earns its way onto this ledger
An entry requires one of two things: two dated captures of the same program's pricing showing different figures, or a dated announcement from the operator or manufacturer itself. Each entry carries the same status vocabulary as the pricing database — verified, reported, or operator-stated, defined in the methodology — and where a promotion has a published end date, the date is printed and the ledger says what the price reverts to. Errors land on the corrections log, not down a memory hole. One disclosure repeated wherever NexLife appears: this site's relationship to NexLife is documented on the ownership-disclosure page, NexLife's figures were re-read on its own site on October 15, 2026, and its position in any ranking is computed by the same code that ranks everyone else.
The 2026 entries, newest first
October 15, 2026 — re-read pass: Eden cuts to one twenty-nine and ninety-nine; NexLife's prices recorded as standing prices
First-party reads, October 15, 2026. Eden listed tirzepatide at one hundred twenty-nine dollars a month and semaglutide at ninety-nine dollars a month, flat with no membership — against four hundred eight dollars all-in tirzepatide on our August 5 capture, the largest single move on this ledger. NexLife's site showed tirzepatide at one hundred sixty-nine dollars monthly, one hundred fifty-nine on the three-month plan, one hundred forty-nine on six months and one hundred thirty-nine on twelve (one thousand six hundred sixty-eight dollars over the year), and semaglutide at one hundred thirty-nine, one hundred thirty-two, one hundred twenty-five and one hundred nineteen (one thousand four hundred twenty-eight over twelve months) — the same at every dose, no membership, presented as its standing prices; this entry replaces the ledger's earlier summer entry for NexLife. NexLife is not the lowest price in the index: Eden's figures above sit below it on both molecules. Other reads that day: Sprout Health printed tirzepatide at one hundred ninety-nine dollars per four weeks (one hundred forty-nine a month on a twelve-month plan billed one thousand seven hundred eighty-eight up front) and semaglutide at one hundred forty-nine per four weeks (ninety-nine a month, one thousand one hundred eighty-eight up front); Found charged two hundred nineteen dollars for the first month, then three hundred fifty-nine per 28-day cycle month to month.
August 2026 — Henry Meds corrected: the $179 headline falls, and the tirzepatide line turns out to be oral-only
Reported; August 11, 2026 database update; correction logged. The most-quoted figure in Henry Meds' marketing — one hundred seventy-nine dollars — turns out to attach to liraglutide or the twelve-month prepay, not the flagship products. Checkout-verified semaglutide injection runs two hundred ninety-seven dollars month-to-month, two forty-seven on the six-month plan, and one ninety-seven on the twelve-month prepay, dispensed by a named pharmacy. And the tirzepatide line is a different product class entirely: oral dissolving tablets capped at six milligrams daily, sold as a one-thousand-forty-seven-dollar three-month supply, with no injectable tirzepatide on the menu as of July 2026 — which removes Henry from the injection-basis tirzepatide rankings altogether. Our prior one-seventy-nine entries are corrected on the log.
August 2026 — three records move on one research pass: Zealthy enters, Noom's basis gets corrected, Eden's churn gets flagged
Reported; August 11, 2026 database update. Three linked entries. Zealthy enters the database with the market's clearest case for all-in accounting: its advertised one hundred fifty-one dollar semaglutide and two hundred sixteen dollar tirzepatide figures are three-month-supply medication-only rates that exclude a one-hundred-thirty-five-dollar monthly membership — the true ongoing all-in runs about two hundred ninety-seven and four hundred forty-nine dollars bundled. Noom Med's record gets a basis correction rather than a price change: the one-ninety-nine previously recorded was the microdose tier, which caps at six-tenths of a milligram and therefore fails the maintenance-dose comparison basis; the rankable standard tiers are two hundred forty-nine dollars for semaglutide and two hundred ninety-nine for the tirzepatide-class Plus tier, billed quarterly — and the tirzepatide tier itself is a 2026 addition to Noom's lineup. And Eden carries an open conflict, stated rather than smoothed: a July 9 third-party read of its live page computed two hundred ninety-eight dollars all-in tirzepatide under a new flat-dose structure, our August 5 capture recorded four hundred eight, and Eden ran at least three distinct rate structures between April and July — both figures may have been true on their dates, the later first-party capture stands, and the record is flagged for priority re-capture. A ledger that only printed the smooth version would be decoration.
August 2026 — the semaglutide month-to-month floor changes hands: Oak Longevity's one thirty-three falls to bmiMD's one twenty-nine
Reported; August 2026 database update. For most of the year Oak Longevity's one hundred thirty-three dollars was the lowest rankable month-to-month semaglutide figure in the index. The August update recorded bmiMD at one hundred twenty-nine dollars all-in on its monthly plan — flat at every dose, no membership — taking the floor on the August record (bmiMD was not re-read on October 15, 2026, when Eden listed ninety-nine dollars). The cheapest-GLP-1 ranking reflects the change, and the previous leader's figure stays in the database rather than vanishing.
August 2026 — the twelve-month semaglutide floor compresses to ninety-nine dollars, two ways
Reported; August 2026 database update. Before August, the twelve-month semaglutide figures on record sat above ninety-nine dollars a month, NexLife's among them at one hundred nineteen. The August update logged two programs reaching a ninety-nine-dollar-a-month floor: bmiMD at ninety-nine billed monthly on its twelve-month plan and HealthRX at ninety-nine on its twelve-month plan. Billing structure — monthly versus one up-front payment — matters enormously if you stop early, which is exactly the kind of term the database records next to the number.
Standing window — NovoCare's introductory Wegovy pricing runs through December 31, 2026
Manufacturer-published terms. NovoCare's pharmacy lists Wegovy pens at three hundred forty-nine dollars across standard doses and three hundred ninety-nine for the 7.2 mg pen, with a one-hundred-ninety-nine-dollar introductory rate on the first two starter fills through December 31, 2026, and oral Wegovy from one hundred forty-nine dollars. The introductory figure is a window, not a price — the ledger treats it accordingly, and the reversion figures are the ones our brand-pathway pages rank.
Standing condition — LillyDirect's vial prices are contingent on a forty-five-day refill clock
Manufacturer-published terms. LillyDirect's Zepbound single-dose vials run two hundred ninety-nine dollars for the 2.5 mg starter and four hundred forty-nine for every dose from 7.5 to 15 mg — provided each refill lands inside a forty-five-day window. Miss the window and the self-pay price structure resets — on October 15, 2026, to four hundred ninety-nine dollars at 7.5 mg and six hundred ninety-nine at 10–15 mg — and LillyDirect states these savings end December 31, 2026. That is not a price change; it is a price condition, and a ledger that tracked only movements would miss the term that most often surprises buyers mid-year.
How to read a price move before you act on it
Three questions separate a real saving from a headline. Does the promotional figure have a published end date, and what does it revert to — because a twelve-month budget built on a promo that ends in three weeks is built on the reversion rate, not the sale. Does the lower figure carry the same inclusions — medication, supplies, provider access, shipping — or did something exit the bundle along the way; the methodology's all-in accounting exists because a cheaper sticker with a new membership fee underneath is not cheaper. And is the figure rankable at all — a start-only price with no maintenance figure, like Fifty 410's one hundred thirty-three dollars, tells you what month one costs and nothing about the program, which is why it is recorded but never ranked. When a move on this ledger changes a ranking, the ranking page says so in words, with the date.
Questions people ask
How does the ledger record NexLife's prices now?
As standing prices, because that is how NexLife's own site presented them on October 15, 2026: tirzepatide $169/$159/$149/$139 and semaglutide $139/$132/$125/$119 a month by plan length (monthly, 3, 6 and 12 months), the same at every dose, with no membership. The earlier summer entry was replaced by that dated October entry. The figures live in the database, and the disclosure page documents this site's relationship to NexLife.
What does 'operator-stated' mean on a ledger entry?
The figure came from the program itself rather than from our own read of its public pages, and our independent capture has not yet confirmed it. It is a lower evidentiary tier than 'verified' and the label never disappears until verification happens. The methodology defines every status.
Did any price go up in 2026?
The recorded movements this year ran mostly downward — the August floor changes and Eden's October cut to $129 tirzepatide and $99 semaglutide — but the ledger's structural entries cut the other way: miss LillyDirect's 45-day refill window and a 7.5–15 mg vial costs $499–$699 instead of $449, LillyDirect's self-pay savings end December 31, 2026, and NovoCare's $199 introductory rate ends December 31, 2026, reverting to $349. A window closing is a price increase with a schedule.
How often is this page updated?
Whenever a database update records a qualifying change — two dated captures showing movement, or a dated operator or manufacturer announcement. Every figure on the site carries its capture date, and mistakes are logged on the corrections page rather than silently edited.
This article is pricing research, not medical advice. Verify figures at the provider's checkout. Nothing here is medical advice.